Retroperitoneal Fibrosis Research: Current Focus Areas

Retroperitoneal fibrosis (RPF) is an active research area with several promising directions:

1. Etiology and Pathogenesis

• IgG4-related disease (majority of idiopathic RPF)
• Genetic susceptibility (HLA associations)
• Drug-induced (beta-blockers, ergot derivatives, checkpoint inhibitors)
• Malignancy-associated (paraneoplastic)
• Inflammatory/autoimmune triggers

2. Biomarkers

• Serum IgG4, IgG4/IgG ratio
• Complement levels (C3, C4)
• Urinary markers (MCP-1, NGAL)
• Imaging biomarkers (PET-CT SUV, MRI fibrosis scoring)

3. Treatment Optimization

• Glucocorticoids remain first-line
• Steroid-sparing agents: azathioprine, mycophenolate, rituximab (anti-CD20)
• Tamoxifen (historical, limited evidence)
• Biologics: tocilizumab (IL-6R), abatacept (CTLA-4-Ig) in trials

4. Minimally Invasive Techniques

• Laparoscopic/robotic ureterolysis with omental wrap
• Endoscopic stenting as a bridge
• Percutaneous nephrostomy for acute decompression

5. Long-Term Outcomes

• Renal function trajectory
• Cardiovascular risk (accelerated atherosclerosis)
• Quality of life, relapse rates

6. Predictive Modeling

Integrating clinical, serologic, imaging, and genomic data to personalize therapy.

These efforts aim to shift RPF management from reactive to precision medicine.